TrialsgrambetaRCTs are beautiful
ESC Congress 2026Apresentado sex., 28 de ago. · 11:15 GMT+2Hot Line 1Todos os ensaios Hot Line →

SINGLE-AF

2026

The Efficacy and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Intermediate Stroke Risk in Patients With Atrial Fibrillation

In 1,803 patients with atrial fibrillation at intermediate stroke risk, a direct oral anticoagulant reduced the net composite of stroke, embolism, major bleeding and death at 2 years compared with no anticoagulation.

Resultado

Eficácia: Composite of stroke, systemic embolism, ISTH major bleeding and cardiovascular death at 2 yearsHR 0,31 (IC 95% 0,10-0,94) · P = 0,03

Abaixo de 1 a favor de a direct oral anticoagulant, acima de 1 a favor de no anticoagulation.

Taxas de eventos
Diferença absoluta
1,0 pontos
NNT
100

A diferença absoluta e o NNT derivam das taxas de eventos.

Também relatado: Driven by ischaemic stroke (0.1% vs 1.1%). Major bleeding 0.3% vs 0.5%.

Publicação original
Subtema
Stroke prevention
Desenho
Investigator-initiated, multicentre, open-label, superiority RCT with blinded outcome adjudication (PROBE), 1:1, permuted blocks stratified by centre, 24-month follow-up, South Korea
Relevância
Importante: um de vários pilares.
Fonte
Kim D, Lee Y, et al. N Engl J Med. 2026; published online 28 August.doi 10.1056/nejmoa2607978

Discussão e crítica

The first randomised answer for atrial fibrillation with a single stroke risk factor, and it favours anticoagulating. Fewer than 20 primary events across 1,803 patients carry the result: the interval runs to 0.94, so the direction is firmer than the size. Open-label at 18 Korean centres, with an observed event rate far below the planning assumption and an absolute difference of one percentage point.

Discutido em podcasts